Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
18.26
+0.11 (0.63%)
At close: Mar 9, 2026, 4:00 PM EDT
17.76
-0.49 (-2.71%)
After-hours: Mar 9, 2026, 5:17 PM EDT
Pulse Biosciences Revenue
In the year 2025, Pulse Biosciences had annual revenue of $350.00K. Pulse Biosciences had revenue of $264.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$350.00K
Revenue Growth
n/a
P/S Ratio
3,546.12
Revenue / Employee
$3,017
Employees
116
Market Cap
1.24B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DENTSPLY SIRONA | 3.68B |
| Embecta | 1.08B |
| Warby Parker | 871.91M |
| Azenta | 595.03M |
| AtriCure | 534.53M |
| LeMaitre Vascular | 249.60M |
| STAAR Surgical Company | 239.44M |
| BioLife Solutions | 96.21M |
PLSE News
- 16 hours ago - Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Business Wire
- 4 days ago - Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - Business Wire
- 5 days ago - Pulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - Business Wire
- 17 days ago - Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference - Business Wire
- 17 days ago - Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results - Business Wire
- 4 weeks ago - What's Going With Pulse Biosciences Stock On Monday? - Benzinga